Phase 3, Randomized, Open Label, Active Controlled Study Evaluating the Efficacy and Safety of Three Times Per Week (TIW) Oral Dosing of Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (TRILO2GY)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Vadadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms TRILO2GY
- Sponsors Akebia Therapeutics
- 08 Nov 2017 According to an Akebia Therapeutics media release, the company expects initiating this study later this year or early 2018.
- 10 Aug 2017 New trial record
- 08 Aug 2017 According to an Akebia Therapeutics media release, the company is planning to initiate this trial second half of 2017 and top line data expected by the end of 2018.